← Leaderboards
Igor J Espinoza-Delgado
Aging
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Most similar at Aging
Same institution · by research overlap
Others in their field
Top investigators on “Neoplasm /Cancer Immunotherapy”
- Constance Ann Benson · University Of California, San Diego$84,289,569
- Charles A Coltman · Southwest Oncology Group$65,041,418
- Norman Wolmark · Nsabp Foundation, Inc.$63,095,441
- Robert Turner Schooley · University Of Colorado Denver$42,307,156
- Samuel A Wells · Duke University$32,148,803
- George Wilding · University Of Wisconsin Madison$22,104,400
Research focus
Neoplasm /Cancer ImmunotherapyDrug Screening /EvaluationNeoplasm /Cancer ImmunologyNeoplasm /Cancer ChemotherapyImmunoregulationHuman Therapy EvaluationGene ExpressionBryostatinHuman SubjectHelper T LymphocyteDrug Adverse EffectB Cell LymphomaMonoclonal AntibodyAntineoplasticsClinical Trial Phase IiAntigen Presenting CellClinical Trial Phase ICombination Cancer TherapyClinical ResearchChronic Lymphocytic LeukemiaCellular ImmunityBiotechnologyCell MigrationHuman Tissue
Grant awards (9)
Phase II trial of Bryostatin-1 and rituximab in B cell$0
Z01 · FY2005 · AG
Aging, Cancer, and the Immune System$0
Z01 · FY2005 · AG
Antitumor and immunomodulatory activities of bryostatin-$0
Z01 · FY2005 · AG
Antitumor and immunomodulation: Bryostatin-1/IL-2$0
Z01 · FY2004 · AG
Aging, Cancer, and the Immune System$0
Z01 · FY2004 · AG
Phase II trial of Bryostatin-1 and rituximab in B cell$0
Z01 · FY2004 · AG
Aging, Cancer, and the Immune System$0
Z01 · FY2003 · AG
Phase 2 trial of Bryostatin-1/rituximab in B cell cancer$0
Z01 · FY2003 · AG
Antitumor/immunomodulatory activities--bryostatin-1/IL2$0
Z01 · FY2003 · AG